30 results about "Glucocorticoid" patented technology

The present invention relates to a novel polymorph of (1R,2R,3aS,3bR,10aS,10bR,11S,12aS)-5,10b-difluoro-1-(((fluoromethyl)thio)carbonyl)-11-hydroxyl-2,10a,12a-trimethyl-7-phenyl-1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecylhydrocyclapenta[5,6]napththo[1,2-F]indazole-1-furan-2-carboxylate ester as shown in formula (I), a preparation method therefor, and a use thereof. The crystal form of the present invention has characteristics such as a significant pharmaceutical effect, good stability, high yield, and high purity, and is beneficial for the selection and design of a drug administration route and the determination of a drug preparation process parameter, thereby improving drug production quality.

The present disclosure relates to the technical field of medicinal chemistry, and particularly, to a novel glucocorticoid, a method for preparing same, and use thereof. The novel glucocorticoid comprises a compound represented by formula I, an optical isomer thereof, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the structure of the compound represented by formula I is shown herein. The compound provided by the present disclosure exhibits a high plasma clearance rate, a short half-life, reduced systemic exposure, and enhanced glucocorticoid receptor (GR) selectivity, thereby significantly reducing the adverse effects associated with systemic absorption of the glucocorticoid drug. The present disclosure has significant anti-inflammatory activity in animals with asthma, uveitis, dry eye syndrome, inflammatory bowel disease, psoriasis, and the like. The compound provided by the present disclosure demonstrates good safety, with no abnormal intraocular pressure observed after continuous ocular administrations in guinea pigs and no significant changes in the thickness of the epidermal layer after continuous dermal administrations in rats.

The disclosure provides a method of treatment for glucocorticoid excess in a patient in need thereof, comprising administering to the patient a pseudo-irreversible HSD-1 inhibitor.

The application discloses a preparation method of CCR2+ gamma delta T cells with anti-tumor activity and migration ability, and belongs to the technical field of cells; the method comprises the following steps: step (1), PBMC of peripheral blood of a healthy person is extracted, inoculated into complete culture medium, and added with zoledronic acid, IL-15 and metformin, and then is cultured in a T25 culture bottle; step (2), complete culture medium is supplemented, the cell concentration is adjusted, and then the cells are transferred into a T75 culture bottle for culture; step (3), complete culture medium is supplemented, the cell concentration is adjusted, glucocorticoid and nicotinamide are added, and then the cells are transferred into a T150 culture bottle for culture; step (4), cells are collected at D6, rinsed with normal saline, resuspended with complete culture medium, the cell concentration is adjusted, and then the cells are inoculated into a T300 culture bottle for culture; and step (5), complete culture medium is supplemented every two days from D8 to D16, the cell concentration is maintained, and then the cells are harvested at D16 to obtain CCR2+ gamma delta T cells.

This invention discloses a sodium alginate cross-linked matrix metalloproteinase-sensitive peptide-loaded dexamethasone sodium phosphate hydrogel and its preparation method. The dexamethasone-loaded hydrogel has good injectability. After injection, it is cleaved by MMPs at the site of inflammation in an inflammatory environment to release dexamethasone, exhibiting good sustained-release effect. It achieves targeted and long-acting treatment of inflammatory arthritis, osteoarthritis or other inflammatory diseases, and reduces the frequency of repeated intra-articular injections of glucocorticoids.

Provided is a product containing lysozyme that helps improve oral mucosa-related fibrosis. Lysozyme is found for the first time to have a significant improvement effect on oral mucosa-related fibrosis. Compared with anti-inflammatory drugs such as glucocorticoids commonly used at present, the product has a better improvement effect. Meanwhile, lysozyme is highly safe and can be used as both a drug and food, and has a good application prospect in improving oral mucosa-related fibrosis.

The disclosure provides a method of treatment for glucocorticoid excess in a patient in need thereof, comprising administering to the patient a pseudo-irreversible HSD-1 inhibitor.

A nanoliposome suspension for soft aerosol spray and its preparation method are disclosed. The active ingredient of the nanoliposome suspension is selected from the following combinations: inhaled glucocorticoids, long / short-acting β2 receptor agonists and long / short-acting anticholinergic drugs (LAMA / SAMA), inhaled glucocorticoids, long / short-acting β2 receptor agonists and long / short-acting anticholinergic drugs, inhaled glucocorticoids and long / short-acting β2 receptor agonists, inhaled glucocorticoids and long / short-acting anticholinergic drugs; the active ingredient is encapsulated in nanoliposomes, which are prepared using cholesterol and phospholipids.

The application discloses a pea peptide mixture with calcium binding and osteogenesis promoting effects and application thereof, wherein the pea peptide mixture is derived from protein components in a by-product of pea starch extraction, is obtained through alkaline protease and papain enzymolysis and separation and purification, and is rich in aspartic acid and glutamic acid residues. The pea peptide mixture can effectively bind with calcium ions, the pea peptide mixture can promote calcium ion delivery in osteoblasts, improve alkaline phosphatase activity, and promote osteoblast differentiation, the osteogenesis promoting effect of the pea peptide mixture is related to epidermal growth factor receptor EGFR and downstream PI3K-Akt signal pathway regulation. The pea peptide mixture can improve glucocorticoid-induced zebrafish bone mass reduction, and up-regulate mRNA expression levels of ALP, EGFR, PI3K and Akt and other genes related to osteogenesis. The pea peptide mixture has both functions and nutrition, can be used for preparing products for promoting osteogenesis, improving bone mass, improving bone mass reduction and assisting in improving osteoporosis, and has a wide application prospect in the field of bone health.

This invention provides a method for treating postoperative nausea and vomiting using buccal acupuncture combined with a triple antiemetic regimen. The method employs a combined intervention of buccal acupuncture and a triple antiemetic regimen. The triple regimen consists of a 5-HT3 receptor antagonist, a glucocorticoid, and a dopamine receptor antagonist, administered intravenously in two separate doses. The buccal acupuncture uses CA-2 (upper jiao), CA-3 (middle jiao), and CA-4 (lower jiao) as core acupoints, with auxiliary and reinforcing acupoints added based on the surgical site and high-risk groups. A standardized procedure of pecking stimulation is applied, along with a corresponding postoperative remedial antiemetic medication regimen. This invention organically combines multi-target drug blockade with buccal acupuncture's visceral regulation, synergistically enhancing the antiemetic effect, reducing the incidence of nausea and vomiting, and decreasing the need for remedial medication. The regimen is highly standardized, widely adaptable, and can meet the postoperative nausea and vomiting control needs of various surgeries and high-risk groups. It exhibits good safety, strong repeatability, and high clinical application value.

This invention relates to a novel polymorph of (1R,2R,3aS,3bR,10aS,10bR,11S,12aS)-5,10b-difluoro-1-(((fluoromethyl)thio)carbonyl)-11-hydroxy-2,10a,12a-trimethyl-7-phenyl-1,2,3,3a,3b,7,10,10a,10b,11,12,12a-dodecylhydrocyclopenta[5,6]naphtho[1,2-F]indazole-1-ylfuran-2-carboxylic acid ester as shown in formula (I), its preparation method, and its uses. The polymorph of this invention exhibits significant efficacy, good stability, high yield, and high purity, which is helpful for the selection and design of drug delivery routes and the determination of pharmaceutical formulation process parameters, thereby improving the quality of drug production. (I)

The application discloses a kind of drugs for treating glucocorticoid glaucoma.The application finds by experiment, Rho kinase inhibitor can inhibit RhoA-ROCK signal pathway, destroy glucocorticoid-induced cytoskeleton remodeling and reduce extracellular matrix deposition.At the same time, 10 μM or less concentration, no toxic side effects to cell growth, while significantly inhibiting RhoA-ROCK signal pathway.The experimental results suggest that RKI1447 can change the morphology of trabecular meshwork cells and inhibit cell migration, thereby regulating aqueous humor drainage, reducing intraocular pressure, and thereby treating glucocorticoid glaucoma.The application provides the application of Rho kinase inhibitor RKI1447 in the preparation of glucocorticoid glaucoma drugs.

The application belongs to the field of pharmaceutical chemistry, and particularly relates to a glucocorticoid prodrug, a preparation method and application thereof. The glucocorticoid prodrug has low solubility, is suitable for preparation of a long-acting sustained-release preparation, and compared with existing dexamethasone palmitate preparations on the market, the compound of the application provides more excellent long-acting sustained-release effect, while effectively reducing systemic drug exposure, thereby minimizing or avoiding systemic side effects possibly caused by glucocorticoids.

The disclosure provides a method of treatment for glucocorticoid excess in a patient in need thereof, comprising administering to the patient a pseudo-irreversible HSD-1 inhibitor.

The application discloses a method for evaluating the concentration and combined effect of a glucocorticoid mixture in a sample, and relates to the technical field of biology. The method analyzes the relationship among concentration, time and effect according to a two-phase mechanism of receptor-ligand binding dissociation kinetics, innovatively constructs a two-phase response surface model of dexamethasone concentration, time and effect (dexamethasone model), and introduces a two-phase response surface model of glucocorticoid mixture concentration, time and effect in a sample (sample model) with the index of combined effect. The contributions of time and concentration to the effect and the two-phase complex scene are comprehensively considered, and the reasonable and scientific evaluation of the concentration and combined effect of the glucocorticoid mixture in the sample is realized without losing accuracy by combining the Levenberg-Marquardt algorithm with the Jacobian matrix method. The method provides a solution for evaluating the concentration (in terms of dexamethasone) of the glucocorticoid mixture in a sample and analyzing the combined effect based on a cell strain.

The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.In one embodiment, the present invention provides a method of treating fatty liver disease. The method includes administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I, thereby treating the fatty liver disease, wherein the compound of Formula I has the structure (I).

The application discloses application of eucalyptus oil preparation in skin inflammation treatment, the dosage form of the eucalyptus oil preparation is one of cream, ointment, liniment, spirit, mud film, spray and dressing, the eucalyptus oil preparation contains eucalyptol, the content of the eucalyptol is 1% or 2.5%, when the dosage form of the eucalyptus oil preparation is cream, different potency glucocorticoids are additionally added in the eucalyptus oil preparation to form a compound preparation, when the dosage form of the eucalyptus oil preparation is liniment, glycerol is added in the eucalyptus oil preparation, when the dosage form of the eucalyptus oil preparation is mud film, the mud film is mud-like facial mask prepared by mud film powder and eucalyptus oil.The several new dosage forms provided by the application have the advantages of convenient storage, easy carrying and convenient use under the premise of ensuring treatment effect, and the mud film preparation is extremely friendly to female skin inflammation patients.

This invention discloses the application of sulfadimidine in the preparation of drugs for treating osteoarthritis. This invention is the first to demonstrate the significant efficacy of intra-articular injection of sulfadimidine in the treatment of osteoarthritis (OA); the results show that sulfadimidine can not only significantly relieve the symptoms of osteoarthritis but also improve the metabolic function of chondrocytes, thereby slowing the progression of arthritis. Traditional treatment methods mainly include intra-articular injection of anesthetic drugs, joint lubricants (such as sodium hyaluronate), glucocorticoids, and platelet-rich plasma (PRP). However, these methods each have limitations, such as significant short-term effects but potential long-term side effects. Sulfamidine, as a novel treatment method, not only has good efficacy but also fewer side effects, providing a new approach to the drug treatment of osteoarthritis.

The present invention relates to a novel polymorph of (8R,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-8,9,10,11,12,13,14,15,16,17-decahydro-3H-cyclopenta[α]phenanthrene-17-furan-2-carboxylate represented by formula (I), a preparation method therefor and a use thereof.

This invention provides a mesenchymal stem cell culture medium, its preparation method, and its application. The mesenchymal stem cell culture medium of this invention includes a basal culture medium and functional additives. The functional additives include: recombinant human albumin, recombinant transferrin, recombinant bone morphogenetic protein; recombinant insulin or insulin-like growth factor, recombinant fibroblast growth factor, recombinant epidermal growth factor, recombinant platelet-derived growth factor; thyroid hormones, ethanolamine, carnitine, glucocorticoid regulators, retinoic acid compounds; heparin sodium, signal-regulating lipids, cholesterol, DL-α-tocopherol acetate, linolenic acid, oleic acid, stearic acid; prolactin F68, and Tween 80. The mesenchymal stem cell culture medium of this invention does not contain immunogenic proteins or blood products derived from animals or humans. All components can be supplied with GMP-compliant raw materials and the process can be controlled, ensuring the controllability, safety, and reproducibility of the culture process.

The present invention relates to the combination therapy of anti-GPRC5D / anti-CD3 bispecific antibodies with proteasome inhibitors. The combination therapy may further comprise a glucocorticosteroid.

The application discloses application of C-type lectin-like receptor-1 as a therapeutic marker in fungal keratitis, and provides a kit for evaluating a use time of a glucocorticoid drug in the treatment of fungal keratitis. The C-type lectin-like receptor-1 can be used as a biomarker to simply and safely judge the use time of the glucocorticoid drug in the fungal keratitis, and has important significance in guiding clinical decision-making.

The present disclosure provides novel and improved combination therapies for the treatment of glucocorticoid-mediated diseases using HSD-1 inhibitors and glucocorticoids.

The anti-inflammatory composition may be administered to a subject in need thereof to prevent or reduce inflammation, including inflammation resulting from asthma. The anti-inflammatory composition may comprise both onion bulb extract and one or more glucocorticosteroids, particularly a low-dose glucocorticosteroid. The anti-inflammatory composition may be administered to a subject at risk of developing asthma to prevent the progression of asthma. The anti-inflammatory composition may act by reducing pEGFR levels, or by inhibiting other inflammatory pathways.

The disclosure provides a method of treatment for glucocorticoid excess in a patient in need thereof, comprising administering to the patient a pseudo-irreversible HSD-1 inhibitor.

The application discloses a kind of compound pharmaceutical composition containing PDE-3 / 4 inhibitor, pharmaceutical preparation and preparation method and application thereof, belong to medical technology field.For the high adverse reaction risk of existing COPD treatment drug, poor patient compliance, heavy economic burden, lack of compound inhalation preparation suitable for severe patients;And the physicochemical properties of different active ingredients are greatly different, it is difficult to stably disperse, PDE-3 / 4 inhibitor wet heat sterilization is easy to generate impurities and other problems.The composition of the application includes PDE-3 / 4 inhibitor, glucocorticoid / JAK inhibitor anti-inflammatory component and LABA / LAMA long-acting bronchodilator.Using polysorbate 80-hydroxypropyl betacyclodextrin stabilizing system, the wet heat sterilization process is optimized, the sterilization concentration is controlled to be 100mg / mL, the process impurities are greatly reduced, the product purity and safety are improved, and sterile inhalation suspension is prepared, which can be atomized to treat chronic bronchitis related COPD.

The disclosure provides a method of treatment for glucocorticoid excess in a patient in need thereof, comprising administering to the patient a pseudo-irreversible HSD-1 inhibitor.

Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.